Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143201829> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2143201829 endingPage "389" @default.
- W2143201829 startingPage "384" @default.
- W2143201829 abstract "OBJECTIVE: To determine if dual individualization of cefmenoxime dosing is cost-effective. DESIGN: Retrospective, pharrnacoeconomic decisionanalysis of two consecutively conductedprospective clinical studies. PATIENTS: Patientswithdocumentedgram-negative nosocomial pneumoniawere evaluated. Thirty-three patients received cefmenoximeat standarddosing and 28 patients received doses according to dual individualization methodology. MAIN OUTCOME MEASURE: Antibiotic and infection-related costs were compared between groups. The number of hospital antibiotic days and costs incurred on those days were also evaluated. A decision model was constructed to characterize differences in treatment outcome. Probabilities with in the decision tree were derived from 61 evaluable patients. Cost-effectiveness and incremental cost-effectiveness ratios were calculated. Sensitivity analysis was performed by varying out come probabilities, antibiotic prices, and hospital room costs. RESULTS: Antibiotic and infection-related costs (mean ± SEM) were $848 ± 78 for standard cefmenoxime dosing and $1123 ± 128 for dual individualization (p<0.05). Total hospital costs were $10 660 ± 1432 or standard dosing and $11 700 ± 1900 for dual individualization (p>0.05). Median antibiotic length of stay (ALOS) was 15.2 and 12.7 days for standard and dual individualization methodologies, respectively (p>0.05). Incremental analysis of cost effectiveness indicated that a similar reduction in length of stay for 259 dual individualization patients would save $321 808 annually. CONCLUSIONS: Sensitivity analysis indicates that by reducing ALOS, dual individualization could be a cost-effective method of betalactam dosing for patients with pneumonia. A prospective study should be conducted to validate these findings." @default.
- W2143201829 created "2016-06-24" @default.
- W2143201829 creator A5011015456 @default.
- W2143201829 creator A5050273468 @default.
- W2143201829 date "1994-03-01" @default.
- W2143201829 modified "2023-09-26" @default.
- W2143201829 title "Pharmacoeconomic Analysis of Cefmenoxime Dual Individualization in the Treatment of Nosocomial Pneumonia" @default.
- W2143201829 cites W1966992922 @default.
- W2143201829 cites W1998704615 @default.
- W2143201829 cites W2007779039 @default.
- W2143201829 cites W2014011239 @default.
- W2143201829 cites W2020081978 @default.
- W2143201829 cites W2027283887 @default.
- W2143201829 cites W2030447368 @default.
- W2143201829 cites W2046815420 @default.
- W2143201829 cites W2061047185 @default.
- W2143201829 cites W2062951917 @default.
- W2143201829 cites W2072174242 @default.
- W2143201829 cites W2073746804 @default.
- W2143201829 cites W2077333041 @default.
- W2143201829 cites W2081352279 @default.
- W2143201829 cites W2093518574 @default.
- W2143201829 cites W2101499551 @default.
- W2143201829 cites W2128191136 @default.
- W2143201829 cites W4205780035 @default.
- W2143201829 cites W4239953570 @default.
- W2143201829 cites W4293242440 @default.
- W2143201829 doi "https://doi.org/10.1177/106002809402800316" @default.
- W2143201829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8193431" @default.
- W2143201829 hasPublicationYear "1994" @default.
- W2143201829 type Work @default.
- W2143201829 sameAs 2143201829 @default.
- W2143201829 citedByCount "36" @default.
- W2143201829 countsByYear W21432018292014 @default.
- W2143201829 countsByYear W21432018292020 @default.
- W2143201829 crossrefType "journal-article" @default.
- W2143201829 hasAuthorship W2143201829A5011015456 @default.
- W2143201829 hasAuthorship W2143201829A5050273468 @default.
- W2143201829 hasConcept C126322002 @default.
- W2143201829 hasConcept C177713679 @default.
- W2143201829 hasConcept C2776738588 @default.
- W2143201829 hasConcept C2777288759 @default.
- W2143201829 hasConcept C2777914695 @default.
- W2143201829 hasConcept C2983335822 @default.
- W2143201829 hasConcept C33923547 @default.
- W2143201829 hasConcept C42475967 @default.
- W2143201829 hasConcept C501593827 @default.
- W2143201829 hasConcept C71924100 @default.
- W2143201829 hasConcept C86803240 @default.
- W2143201829 hasConcept C89423630 @default.
- W2143201829 hasConceptScore W2143201829C126322002 @default.
- W2143201829 hasConceptScore W2143201829C177713679 @default.
- W2143201829 hasConceptScore W2143201829C2776738588 @default.
- W2143201829 hasConceptScore W2143201829C2777288759 @default.
- W2143201829 hasConceptScore W2143201829C2777914695 @default.
- W2143201829 hasConceptScore W2143201829C2983335822 @default.
- W2143201829 hasConceptScore W2143201829C33923547 @default.
- W2143201829 hasConceptScore W2143201829C42475967 @default.
- W2143201829 hasConceptScore W2143201829C501593827 @default.
- W2143201829 hasConceptScore W2143201829C71924100 @default.
- W2143201829 hasConceptScore W2143201829C86803240 @default.
- W2143201829 hasConceptScore W2143201829C89423630 @default.
- W2143201829 hasIssue "3" @default.
- W2143201829 hasLocation W21432018291 @default.
- W2143201829 hasLocation W21432018292 @default.
- W2143201829 hasOpenAccess W2143201829 @default.
- W2143201829 hasPrimaryLocation W21432018291 @default.
- W2143201829 hasRelatedWork W1769504474 @default.
- W2143201829 hasRelatedWork W2080308441 @default.
- W2143201829 hasRelatedWork W2092505418 @default.
- W2143201829 hasRelatedWork W2155814936 @default.
- W2143201829 hasRelatedWork W2162788500 @default.
- W2143201829 hasRelatedWork W2247376599 @default.
- W2143201829 hasRelatedWork W2372593737 @default.
- W2143201829 hasRelatedWork W2400401078 @default.
- W2143201829 hasRelatedWork W2409546295 @default.
- W2143201829 hasRelatedWork W88861556 @default.
- W2143201829 hasVolume "28" @default.
- W2143201829 isParatext "false" @default.
- W2143201829 isRetracted "false" @default.
- W2143201829 magId "2143201829" @default.
- W2143201829 workType "article" @default.